Pre-emptive pangenotypic direct acting antiviral therapy in donor HCV-positive to recipient HCV-negative heart transplantation: an open-label study.

[1]  P. Camp,et al.  Heart and Lung Transplants from HCV‐Infected Donors to Uninfected Recipients , 2019, The New England journal of medicine.

[2]  R. Hasz,et al.  Transplanting hepatitis C virus–infected hearts into uninfected recipients: A single‐arm trial , 2019, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[3]  T. Ayer,et al.  Cost Effectiveness of Transplanting HCV‐Infected Livers Into Uninfected Recipients With Preemptive Antiviral Therapy , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[4]  S. Pungpapong,et al.  Transplantation of HCV‐infected organs into uninfected recipients: Advance with caution , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[5]  R. Hayes,et al.  Early outcomes using hepatitis C-positive donors for cardiac transplantation in the era of effective direct-acting anti-viral therapies. , 2018, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[6]  T. Ayer,et al.  Transplanting hepatitis C virus–positive livers into hepatitis C virus–negative patients with preemptive antiviral treatment: A modeling study , 2018, Hepatology.

[7]  L. Kucirka,et al.  The Drug Overdose Epidemic and Deceased-Donor Transplantation in the United States , 2018, Annals of Internal Medicine.

[8]  S. Hall,et al.  The New Direct Antiviral Agents and Hepatitis C in Thoracic Transplantation: Impact on Donors and Recipients , 2018, Current Transplantation Reports.

[9]  D. Segev,et al.  Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C VirusInfected Donors to Noninfected Recipients , 2018, Annals of Internal Medicine.

[10]  M. Sulkowski,et al.  Utilization of hepatitis C virus RNA–positive donor liver for transplant to hepatitis C virus RNA–negative recipient , 2018, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[11]  G. Klintmalm,et al.  The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[12]  S. Pol,et al.  Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment , 2017, The New England journal of medicine.

[13]  J. Fishman,et al.  Utilization of increased risk for transmission of infectious disease donor organs in solid organ transplantation: Retrospective analysis of disease transmission and safety , 2017, Transplant infectious disease : an official journal of the Transplantation Society.

[14]  S. Mauss,et al.  Reply to: "Negotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030". , 2017, Journal of hepatology.

[15]  R. Hasz,et al.  Trial of Transplantation of HCV-Infected Kidneys into Uninfected Recipients. , 2017, The New England journal of medicine.

[16]  A. Humar,et al.  Successful Lung Transplantation From Hepatitis C Positive Donor to Seronegative Recipient , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[17]  Ashesh P. Shah,et al.  Successful treatment of donor‐derived hepatitis C viral infection in three transplant recipients from a donor at increased risk for bloodborne pathogens , 2017, Transplant infectious disease : an official journal of the Transplantation Society.

[18]  T. Asselah,et al.  Direct‐acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN‐free treatment and future perspectives , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[19]  T. Asselah,et al.  Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. , 2015, The New England journal of medicine.

[20]  B. Whitson,et al.  Donor selection in heart transplantation. , 2014, Journal of thoracic disease.

[21]  E. Yoshida,et al.  A concise review of hepatitis C in heart and lung transplantation. , 2011, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[22]  I. Hutchinson,et al.  Impact of Hepatitis C Infection on Outcomes After Heart Transplantation , 2009, Transplantation.

[23]  M. Berenguer.  Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. , 2008, Journal of hepatology.

[24]  M. Berenguer,et al.  Clinical Benefits of Antiviral Therapy in Patients with Recurrent Hepatitis C Following Liver Transplantation , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[25]  Ajay K Israni,et al.  Hepatitis C virus seropositivity in organ donors and survival in heart transplant recipients. , 2006, JAMA.

[26]  G. Foster,et al.  Treatment of HCV infection with pegylated interferons , 2005 .

[27]  E. Tuzcu,et al.  Donor hepatitis-C seropositivity is an independent risk factor for the development of accelerated coronary vasculopathy and predicts outcome after cardiac transplantation. , 2004, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[28]  M. Mehra,et al.  Allograft transmission of hepatitis C virus infection from infected donors in cardiac transplantation , 2003, Transplantation.

[29]  H. Laks,et al.  Hepatitis C‐positive Donors in Heart Transplantation , 2002, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[30]  F. Farinati,et al.  HBV and HCV infections in heart transplant recipients. , 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[31]  P. Pfau,et al.  Hepatitis C transmission and infection by orthotopic heart transplantation. , 2000, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[32]  M. Goormastic,et al.  Outcome ofDe Novohepatitis C virus infection in heart transplant recipients , 1999, Hepatology.

[33]  D. Persing,et al.  Prevalence and outcome of hepatitis C infection among heart transplant recipients. , 1995, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[34]  A. Levey,et al.  Transmission of hepatitis C virus by organ transplantation. , 1991, The New England journal of medicine.